Jennifer Long
Nurse Practitioner · Middletown, OHNPI 1972385698
Payments from drug & device makers
Across 127 payments — averaging $20.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$678
- GSK$511
- Regeneron Healthcare Solutions, Inc.$303
- Grifols USA, LLC$218
- Axsome Therapeutics, Inc.$154
- Sanofi$126
- plus $619 from 12 others
What the payments were for
- Food & beverage$2,51296%
- Education$974%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 30 | $678 |
| GSK | 33 | $511 |
| Regeneron Healthcare Solutions, Inc. | 16 | $303 |
| Grifols USA, LLC | 9 | $218 |
| Axsome Therapeutics, Inc. | 8 | $154 |
| Sanofi | 5 | $126 |
| Baxter Healthcare | 4 | $97 |
| Sanofi-aventis U.S. LLC | 1 | $80 |
| Insmed, Inc. | 3 | $75 |
| Mylan Specialty L.p. | 3 | $66 |
| United Therapeutics Corporation | 3 | $66 |
| Amgen | 3 | $64 |
| Viatris Specialty LLC | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $38 |
| Boehringer Ingelheim | 2 | $34 |
| Pulmonx Corporation | 1 | $33 |
| Philips North America LLC | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
How this compares
$2,610 in reported general payments places this provider in the 90th percentile of 4,700 nurse practitioner providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 174 | $209,153 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 43 | $45,362 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $15,047 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 21 | $14,637 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 12 | $7,676 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 14 | $7,426 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 286 | $6,823 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 44 | $4,438 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 19 | $1,943 |
| Ventolin HfaAlbuterol Sulfate | 16 | $888 |
| Fluticasone Propionate | 61 | $641 |
| Azelastine Hcl | 17 | $590 |
| Montelukast Sodium | 38 | $331 |
| Azithromycin | 51 | $322 |
| Prednisone | 84 | $306 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $511 | $238,837216 claims |
| AstraZenecaBreztri Aerosphere | $678 | $45,36243 claims |
| Boehringer IngelheimCombivent Respimat, Stiolto Respimat | $34 | $15,10226 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,700 nurse practitioner providers in Ohio.
Other nurse practitioner in Middletown
- Margaret BobonichCleveland$235K
- Mary GallagherWestlake$229K
- Sonia HissettCincinnati$179K
- Ashley TaylorNew Albany$107K
- Beth FaimanCleveland$101K
- Katherine AlexanderColumbus$99K
- Tiffany JonesCincinnati$99K
- Kate NewmanWestlake$78K
- Daniella GerySouth Euclid$73K
- Amy HazelCanton$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.